Montelukast Für Kinder Ab 6 Monaten Bis 5 Jahre Teva (Montelukast Sodium)

• Montelukast acts on the leukotriene pathway to control respiratory and allergic conditions in young children.
• Asthma: reduces frequency and severity of wheezing episodes and improves overall lung function.
• Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes associated with seasonal allergies.
• Prevention of exercise‑induced bronchospasm: helps prevent bronchoconstriction triggered by physical activity.

• Montelukast Sodium selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes from binding to airway smooth‑muscle cells and inflammatory cells. This inhibition reduces leukotriene‑mediated bronchoconstriction, mucus secretion, and vascular permeability, thereby decreasing airway inflammation and hyper‑responsiveness associated with asthma and allergic rhinitis.

Montelukast is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

• Headache: mild to moderate pain often transient.
• Abdominal pain: discomfort or cramping in the stomach area.
• Cough: occasional dry cough without infection.
• Sore throat: irritation or scratchy feeling in the throat.
• Nausea: feeling of unease or urge to vomit.
• Diarrhea: loose stools occurring intermittently.

Serious or Rare Side Effects

• Allergic reactions: rash, angioedema, or urticaria requiring medical attention.
• Neuropsychiatric events: agitation, anxiety, depression, or suicidal thoughts.
• Hepatic enzyme elevation: abnormal liver function tests observed in rare cases.
• Stevens‑Johnson syndrome: severe skin reaction, extremely rare but requires immediate care.

• Montelukast should be used with awareness of specific safety considerations.
• Age limitation: use only in children six months to five years as prescribed.
• Monitoring: observe for neuropsychiatric symptoms such as mood changes or agitation.
• Contraindications: avoid in patients with known hypersensitivity to montelukast or any formulation component.
• Drug interactions: review concomitant medications for potential pharmacokinetic effects.
• Pregnancy and lactation: safety not fully established; use only if potential benefit justifies the risk.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce montelukast plasma concentrations and efficacy.
• Phenobarbital: can lower drug levels, potentially compromising therapeutic effect.

Moderate Interactions (Monitor Closely)

• Warfarin: occasional reports of altered INR; monitor coagulation parameters.
• Phenylephrine or other sympathomimetics: may increase cardiovascular side effects.
• Other leukotriene modifiers (e.g., zafirlukast): concurrent use offers no added benefit and may increase adverse event risk.